Acta Neurol Scand: Peranpane's efficacy as an add-on to epilepsy treatment

The purpose of this study is to determine the efficacy and safety of adding peramparone to a single drug treatment for the treatment of theepilepsyseizures associated with or not accompanied by a secondary systemic strong-cheicary seizurein this multicenter, open-label trial, the group of patients were treated with peramparationsPeranpal increases by 2mg/d every 2 weeks during the 12-week drip regularperiodThe patient then enters a 24-week maintenance periodThe main objective was to investigate the 50% response rate of the total seizure frequency, and the 75% and 100% response rates to be secondary targetsTreatment of sudden adverse events (TEAEs) and adverse drug reactions were recordedWe conducted an after-the-fact analysis to study the effects of drop-rate and different accompanying AEDs on the efficacy and safety of Peranpalin the 85 patients analyzed, had a 50.0% (95% confidence interval) (CI) (CI) (CI: 69.9-87.9), 71.8% (95% CI: 61.0-81.0) and 47.1% (95% CI: 36.1-58.2) with 50%, 75% and 100The 50%, 75% and 100% response rates were 87.5% (95% CI:61.7-98.5), 87.5% (95% CI: 61.7-98.5) and 75.0% (95% CI:47.6-92.7) respectivelyThe most common TEAE were dizziness (50.0%), drowsiness (9.8%) and headache (8.8%)When layered by AEDs used at the same time, the efficacy and safety of Peranpane are better, the titer is slower, and the titer is relatively consistentin summary, the results show that in patients with episode attacks, accompanied or not accompanied by secondary systemic seizures, Peranpane as the first additional drug for single drug therapy, the effect is good, good tolerance